Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Ischemic stroke is a serious condition associated with severe functional disability and high mortality, however; effective therapy remains elusive. Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been shown to exert additional non-glycemic benefits including anti-apoptotic effects in different disease settings. Thereby, this study was designed to investigate the ameliorative effect of empagliflozin on the neuronal apoptosis exhibited in cerebral ischemia/reperfusion (I/R) in a rat model targeting HIF-1α/VEGF signaling which is involved in this insult. Global cerebral I/R injury was induced in male Wistar rats through occlusion of the bilateral common carotid arteries for 30 min followed by one-hour reperfusion. Empagliflozin doses of 1 and 10 mg/kg were administered 1 and 24 h after reperfusion. In I/R-injured rats, empagliflozin treatments significantly reduced infarct size and enhanced neurobehavioral functions in a dose-dependent manner. The drug alleviated neuronal death and cerebral injury inflicted by global ischemia as it suppressed neuronal caspase-3 protein expression. In parallel, protein expressions of HIF-1α and its downstream mediator VEGF were upregulated in the ischemic brain following empagliflozin treatment. The results indicated that empagliflozin attenuates cerebral I/R-induced neuronal death via the HIF-1α/VEGF cascade.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a study assessing cerebral ischemia/reperfusion damage in a rat model, empagliflozin, in a dose-dependant manner, reduced neuronal death, infarct size and ameliorated cognitive impairment via HIF-1α/VEGF signaling [50].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [50]
Citations
Cites
Katan, M., & Luft, A. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1649503 · Cited by 2,137
Garcia, J. H., Wagner, S., Liu, K.-F., & Hu, X.-J. (1995) · Stroke · doi:10.1161/01.str.26.4.627 · Cited by 1,483
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A. V., & Greenberg, D. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17977 · Cited by 1,282
Bederson, J. B., Pitts, L. H., Germano, S. M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. M. (1986) · Stroke · doi:10.1161/01.str.17.6.1304 · Cited by 1,277
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X. O., Logvinova, A., & Greenberg, D. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317977 · Cited by 1,189
Oxidative stress in angiogenesis and vascular disease
Kim, Y.-W., & Byzova, T. V. (2014) · Blood · doi:10.1182/blood-2013-09-512749 · Cited by 701
Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661
Uthman, L., Baartscheer, A., Bleijlevens, B., Schumacher, C. A., Fiolet, J. W. T., Koeman, A., Jancev, M., Hollmann, M. W., Weber, N. C., Coronel, R., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4509-7 · Cited by 610
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Vascular Endothelial Growth Factor as a Target for Anticancer Therapy
Ferrara, N. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-2 · Cited by 574
Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators
Déry, M.-A. C., Michaud, M. D., & Richard, D. E. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.08.012 · Cited by 545
Vascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation
Ramakrishnan, S., Anand, V., & Roy, S. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9531-7 · Cited by 442
Apoptosis and Acute Brain Ischemia in Ischemic Stroke
Radak, D., Katsiki, N., Resanovic, I., Jovanovic, A., Sudar-Milovanovic, E., Zafirovic, S., A. Mousad, S., & R. Isenovic, E. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666161104095522 · Cited by 442
Bergeron, M., Yu, A. Y., Solway, K. E., Semenza, G. L., & Sharp, F. R. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00845.x · Cited by 412
Baranova, O., Miranda, L. F., Pichiule, P., Dragatsis, I., Johnson, R. S., & Chavez, J. C. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0449-07.2007 · Cited by 350
Sa-nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.08.005 · Cited by 274
Rosen, L. S. (2002) · Cancer Control · doi:10.1177/107327480200902s05 · Cited by 268
Lee, H. J., Kim, K. S., Park, I. H., & Kim, S. U. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000156 · Cited by 240
Plate, K. H., Beck, H., Danner, S., Allegrini, P. R., & Wiessner, C. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199906000-00010 · Cited by 236
Ojima, A., Matsui, T., Nishino, Y., Nakamura, N., & Yamagishi, S. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0034-1395609 · Cited by 223
Simard, J. M., Geng, Z., Woo, S. K., Ivanova, S., Tosun, C., Melnichenko, L., & Gerzanich, V. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.120 · Cited by 211
Zhang, Y., Nakano, D., Guan, Y., Hitomi, H., Uemura, A., Masaki, T., Kobara, H., Sugaya, T., & Nishiyama, A. (2018) · Kidney International · doi:10.1016/j.kint.2018.05.002 · Cited by 206
Mu, D., Jiang, X., Sheldon, R. A., Fox, C. K., Hamrick, S. E. G., Vexler, Z. S., & Ferriero, D. M. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.020 · Cited by 179
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
Chang, Y.-K., Choi, H., Jeong, J. Y., Na, K.-R., Lee, K. W., Lim, B. J., & Choi, D. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158810 · Cited by 176
Caspase-3 and the regulation of hypoxic neuronal death by vascular endothelial growth factor
Jin, K., Mao, X., Parmentier‐Batteur, S., McEachron, E., Leahy, A. A., & Greenberg, D. A. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00154-3 · Cited by 166
Bessho, R., Takiyama, Y., Takiyama, T., Kitsunai, H., Takeda, Y., Sakagami, H., & Ota, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-51343-1 · Cited by 162
Andreadou, I., Efentakis, P., Balafas, E., Togliatto, G., Davos, C. H., Varela, A., Dimitriou, C. A., Nikolaou, P.-E., Maratou, E., Lambadiari, V., et al. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.01077 · Cited by 159
Effects of apoptosis-related proteins caspase-3, Bax and Bcl-2 on cerebral ischemia rats
LIU, G., WANG, T., WANG, T., SONG, J., & ZHOU, Z. (2013) · Biomedical Reports · doi:10.3892/br.2013.153 · Cited by 158
Jin, K., Mao, X. O., Nagayama, T., Goldsmith, P. C., & Greenberg, D. A. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00207-4 · Cited by 153
Dong, Y., Wang, J.-L., Feng, D., Qin, H., Wen, H., Yin, Z., Gao, G., & Li, C. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.7634 · Cited by 146
Ogle, M. E., Gu, X., Espinera, A. R., & Wei, L. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.020 · Cited by 144
Seman, L., Macha, S., Nehmiz, G., Simons, G., Ren, B., Pinnetti, S., Woerle, H. J., & Dugi, K. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.16 · Cited by 136
Expression of the Na+‐d‐Glucose Cotransporter SGLT1 in Neurons
Poppe, R., Karbach, U., Gambaryan, S., Wiesinger, H., Lutzenburg, M., Kraemer, M., Witte, O. W., & Koepsell, H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010084.x · Cited by 134
Regional distribution of SGLT activity in rat brain in vivo
Yu, A. S., Hirayama, B. A., Timbol, G., Liu, J., Diez-Sampedro, A., Kepe, V., Satyamurthy, N., Huang, S.-C., Wright, E. M., & Barrio, J. R. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00317.2012 · Cited by 126
Heise, T., Seman, L., Macha, S., Jones, P., Marquart, A., Pinnetti, S., Woerle, H. J., & Dugi, K. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0030-2 · Cited by 126
Cohen, A., Troib, S., Dotan, S., Najmuldeen, H., Yesilkaya, H., Kushnir, T., Shagan, M., Portnoi, M., Nachmani, H., Benisty, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40779-0 · Cited by 118
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Ye, Y., Jia, X., Bajaj, M., & Birnbaum, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6837-3 · Cited by 115
Mechanisms and targets for angiogenic therapy after stroke
Navaratna, D., Guo, S., Arai, K., & Lo, E. H. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.2.8396 · Cited by 112
Ryou, M., Liu, R., Ren, M., Sun, J., Mallet, R. T., & Yang, S. (2012) · Stroke · doi:10.1161/strokeaha.111.620088 · Cited by 90
Harms, K. M., Li, L., & Cunningham, L. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009767 · Cited by 89
Erdogan, M. A., Yusuf, D., Christy, J., Solmaz, V., Erdogan, A., Taskiran, E., & Erbas, O. (2018) · BMC Neurology · doi:10.1186/s12883-018-1086-4 · Cited by 87
Chang, Y., Hsiao, G., Chen, S., Yi-cheng, C. H. E. N., Jiing-han, L. I. N., Lin, K.-H., Chou, D., & Sheu, J. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00514.x · Cited by 83
Arafa, N. M. S., Ali, E. H. A., & Hassan, M. K. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.08.013 · Cited by 76
Jin, K. L., Mao, X. O., Nagayama, T., Goldsmith, P. C., & Greenberg, D. A. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00331-6 · Cited by 74
Li, J., Han, B., Ma, X., & Qi, S. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.012 · Cited by 71
Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
Kramer, C. K., & Zinman, B. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-042017-094221 · Cited by 62
Heeba, G. H., & El-Hanafy, A. A. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.12.001 · Cited by 58
VEGF - A Stimulus for Neuronal Development and Regeneration in the CNS and PNS
Theis, V., & Theiß, C. (2018) · Current Protein and Peptide Science · doi:10.2174/1389203719666180104113937 · Cited by 57
Sanganalmath, S. K., Gopal, P., Parker, J. R., Downs, R. K., Parker, J. C., & Dawn, B. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2885-9 · Cited by 53
Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast
Maae, E., Nielsen, M., Steffensen, K. D., Jakobsen, E. H., Jakobsen, A. K. M., & Sørensen, F. B. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411412599 · Cited by 51
Thomas, L., Grempler, R., Eckhardt, M., Himmelsbach, F., Sauer, A., Klein, T., Eickelmann, P., & Mark, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01518.x · Cited by 50
Zapata-Morales, J. R., Galicia-Cruz, O. G., Franco, M., & Martinez y Morales, F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.526814 · Cited by 48
Hypoxia inducible factor-1 alpha stabilization for regenerative therapy in traumatic brain injury
Khan, M., Khan, H., Singh, I., & Singh, A. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.206632 · Cited by 46
Oerter, S., Förster, C., & Bohnert, M. (2019) · International Journal of Legal Medicine · doi:10.1007/s00414-018-1893-6 · Cited by 43
Otsuka, S., Sakakima, H., Terashi, T., Takada, S., Nakanishi, K., & Kikuchi, K. (2018) · Brain Structure and Function · doi:10.1007/s00429-018-1800-4 · Cited by 40
Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas
Kepe, V., Scafoglio, C., Liu, J., Yong, W. H., Bergsneider, M., Huang, S.-C., Barrio, J. R., & Wright, E. M. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2823-7 · Cited by 39
Dong, Y., Li, Y., Feng, D., Wang, J., Wen, H., Liu, D., Zhao, D., Liu, H., Gao, G., Yin, Z., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.024 · Cited by 39
Vasculogenesis and Angiogenesis in VEGF Receptor-1 Deficient Mice
Ho, V. C., & Fong, G. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2917-7_12 · Cited by 34
周海燕, 马岳峰, 周益锋, 柳子明, Wang, K., & 陈钢 (2003) · PubMed · Cited by 31
Wang, L., Wang, F., Liu, S., Yang, X., Yang, J., & Ming, D. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.12.010 · Cited by 24
Wang, S., & Fan, F. (2019) · Hypertension · doi:10.1161/hyp.74.suppl_1.051 · Cited by 9
Research works printed but not linked: 1
- Zapata-Morales JR, Galicia-Cruz OG, Franco M, y Morales FM (2014) Hypoxia-inducible factor-1α (HIF-1α) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia. J Biol Chem 289:346–357. https://doi.org/10.1074/jbc.M113.526814 · DOI · Paper page
Cited by
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“In a study assessing cerebral ischemia/reperfusion damage in a rat model, empagliflozin, in a dose-dependant manner, reduced neuronal death, infarct size and ameliorated cognitive impairment via HIF-1α/VEGF signaling [50].”
BackgroundInfluentialCai, C., Guo, Z., Chang, X., Li, Z., Wu, F., He, J., Cao, T., Wang, K., Shi, N., Zhou, H., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102288 · Cited by 261
“It is well documented that the intracellular effectors of empagliflozin include extracellular signal-regulated kinase 1/2 [65], phosphoinositide 3-kinase/Akt [18], transforming growth factor β1 [66], nuclear factor κB [67], Janus kinase 2 [67], Sirtuin 1 [68], hypoxia inducible factor 1α [69], protein kinase G Iα [70]…”
BackgroundBiological Functions and Regulatory Mechanisms of Hypoxia-Inducible Factor-1α in Ischemic Stroke
He, Q., Ma, Y., Liu, J., Zhang, D., Ren, J., Zhao, R., Chang, J., Guo, Z., & Yang, Y. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.801985 · Cited by 154
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Tsai, K., Chen, Y., Chiou, T. T., Chu, T., Li, L., Ng, H., Lee, W., & Lee, C. (2021) · Antioxidants · doi:10.3390/antiox10081166 · Cited by 149
Wiciński, M., Wódkiewicz, E., Górski, K., Walczak, M., & Malinowski, B. (2020) · Pharmaceuticals · doi:10.3390/ph13110379 · Cited by 110
“[42] found that empagliflozin, at both low and high doses, attenuated neurological defects in rats of induced ischemia model utilizing occlusion of the carotid arteries.”
Background
Metadata
- Authors
- Abdel-latif, R. G., Rifaai, R. A., & Amin, E. F.
- Affiliations
- Minia University (EG)
- Venue
- Archives of Pharmacal Research
- Published
- 2020-05
- Volume
- 43
- Issue
- 5
- Pages
- 514-525
- ISSN
- 0253-6269 (ISSN-L)
- 1976-3786
- OpenAlex
- W3027004825
- Cited by
- 92
- References
- 62
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 20 · 2023: 15 · 2022: 16 · 2021: 12 · 2020: 1
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Archives of Pharmacal Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- empagliflozin, cerebral ischemia-reperfusion injury, neuronal apoptosis, HIF-1α, vascular endothelial growth factor, ischemic stroke, SGLT2 inhibitors, caspase-3, infarct size, neurobehavioral function, global cerebral ischemia
- MeSH terms
- Administration, Oral, Animals, Benzhydryl Compounds, Brain Ischemia, Disease Models, Animal, Glucosides, Male, Signal Transduction, Reperfusion Injury, Rats, Wistar, Apoptosis, Vascular Endothelial Growth Factors, Rats, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.